Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Mar;26(2):510-518.
doi: 10.1177/11297298231226259. Epub 2024 Feb 5.

Safety and efficacy of a new covered stent in hemodialysis vascular access outflow stenosis: A Brazilian multicenter retrospective study

Affiliations
Multicenter Study

Safety and efficacy of a new covered stent in hemodialysis vascular access outflow stenosis: A Brazilian multicenter retrospective study

Leonardo de Oliveira Harduin et al. J Vasc Access. 2025 Mar.

Abstract

Background: Vascular stenosis commonly leads to dysfunction in hemodialysis vascular access. Although percutaneous transluminal angioplasty is an established treatment, stent utilization has increased in the last decade as an alternative solution to extend the access function. This study evaluated the safety and initial results of a new impermeable covered stent for treating vascular access outflow stenosis.

Methods: Investigators retrospectively analyzed 114 hemodialysis patients treated with polytetrafluorethylene-covered stents from September 2018 to September 2022 across four centers. Lesions treated were de novo or restenotic and located in the venous graft anastomosis, outflow segment, cephalic arch, and basilic swing point. Patients were followed by in-person physical examination at 1, 3, and 6 months, and Duplex ultrasound was performed to evaluate the vascular access circuit and in-stent restenosis. The primary efficacy endpoint was target lesion primary patency at 1, 3, and 6 months. Secondary endpoints included access circuit primary patency and secondary patency at 1, 3, and 6 months. The primary safety endpoint was freedom from local or systemic serious adverse events through 30 days post-procedure.

Results: Forty-four patients had thrombosed access at the initial presentation, and 41 patients presented with recurrent stenosis. The target lesion primary patency rates at 1, 3, and 6 months were 100%, 89.4%, and 74%, respectively. The access circuit primary patency rates were 100% at 1 month, 85% at 3 months, and 62.7% at 6 months. The secondary patency rates at 1, 3, and 6 months were 100%, 96.4%, and 94.6%, respectively. In the adjusted multivariate Cox regression analysis, only recurrent lesions and female gender were associated with reduced primary patency rates. No serious adverse event was observed through the first 30 days post-procedure.

Conclusion: In this retrospective analysis, a new covered stent was shown to be safe and effective for treating peripheral outflow stenosis in vascular access.

Keywords: Hemodialysis; covered stent; stenosis; stent graft; vascular access.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: L.O.H. reports receiving research grants from Merit Medical Systems and Bard BD and consulting or lecture fees from Medtronic, Bard BD, Merit Medical Systems, Scitech Medical©, and Gore. T.A.B., M.G.F., and L.C.A. report receiving research grants from Merit Medical Systems, Scitech Medical©, and Bard BD, as well as consulting and lecture fees from Medtronic, Bard BD, Merit Medical Systems, Scitech Medical©, and Gore. J.P.S.M. received consultancy fees from Fresenius Medical Care Brazil.

Figures

Figure 1.
Figure 1.
Study device: (a) SOLARIS multidirectional, impermeable electrospinning PTFE membrane and (b) three tantalum marker bands (distal/proximal).
Figure 2.
Figure 2.
Example of procedural outcomes in a patient with brachiobasilic AVF with stenosis at the swing point: (a) angiography of a basilic vein transposition with severe stenosis at the swing point identified during a thrombectomy procedure, (b) final angiography after implantation of the Solaris 9 × 60 mm coated stent (stent graft), and (c) control angiography 7 months after the initial procedure without evidence of restenosis.
Figure 3.
Figure 3.
(a) The target lesion primary patency rates were 100% at 1 month, 89.4% at 3 months, and 74% at 6 months, (b) the access circuit primary patency rates were 100% at 1 month, 85% at 3 months, and 62.7% at 6 months, (c) the target lesion secondary patency rates at 1, 3, and 6 months were 100%, 96.4%, and 94.6%, respectively, and (d) target lesion patency by segments 6 months after stent implantation.

References

    1. Saran R, Robinson B, Abbott KC, et al.. US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2018; 71: A7. - PMC - PubMed
    1. Sesso R, Lugon JR. Global dialysis perspective: Brazil. Kidney360 2020; 1: 216–219. - PMC - PubMed
    1. Nerbass FB, Lima HN, Thomé FS, et al.. Brazilian dialysis survey 2021. J Bras Nefrol 2022; 45(2): 192–198. - PMC - PubMed
    1. Lok CE, Huber TS, Lee T, et al.. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis 2020; 75(4 Suppl 2): S1–S164. - PubMed
    1. Arhuidese IJ, Orandi BJ, Nejim B, et al.. Utilization, patency, and complications associated with vascular access for hemodialysis in the United States. J Vasc Surg 2018; 68: 1166–1174. - PubMed

Publication types

MeSH terms

LinkOut - more resources